Author: Newsdesk

Philip Morris International Inc. (PMI) Presents at the 2020 Morgan Stanley Virtual Global Consumer & Retail Conference

Now Forecasts 2020 Full-Year Reported Diluted EPS of Around $5.08, or $5.10 on an Adjusted Basis, Reflecting Organic Growth of Around 6%

NEW YORK–(BUSINESS WIRE)–
Regulatory News:

Philip Morris International Inc.’s (NYSE:PM) Chief Financial Officer, Emmanuel Babeau, addresses investors today at the Morgan Stanley Virtual Global Consumer & Retail Conference.

The presentation and Q&A session will be conducted in a virtual format, beginning at approximately 10:00 a.m. Eastern Time. A live video webcast of the entire PMI session will be available, in a listen-only mode, at www.pmi.com/2020morganstanley. Presentation slides will be available on the same site.

An archived copy of the webcast will be available at www.pmi.com/2020morganstanley until Thursday, December 31, 2020. The archived webcast can also be accessed on iOS or Android devices by downloading PMI’s free Investor Relations Mobile Application at www.pmi.com/irapp.

2020 FULL-YEAR FORECAST

PMI revises its full-year 2020 reported diluted EPS forecast to be around $5.08, at prevailing exchange rates, compared to the previously communicated forecast range of $5.03 to $5.08, provided on October 20, 2020. The revision primarily reflects lower anticipated costs, driven by: further efficiencies related to the commercial engine and digitalization, ongoing business simplification, and adjustments to commercial plans due to the pandemic.

Excluding an unfavorable currency impact, at prevailing exchange rates, of approximately $0.32 per share, a favorable tax item of $0.06 per share, asset impairment and exit costs of $0.04 per share and a fair value adjustment for equity security investments of $0.04 per share, this forecast represents a projected increase of around 6% versus pro forma adjusted diluted EPS of $5.13 in 2019, as detailed in the below table.

2020 Full-Year Forecast
	Full-Year
	2020 Forecast			2019			Organic Growth
Reported Diluted EPS	$5.08			$4.61
Tax items	(0.06	)		(0.04	)
Asset impairment and exit costs	0.04			0.23
Canadian tobacco litigation-related expense				0.09
Loss on deconsolidation of RBH				0.12
Russia excise and VAT audit charge				0.20
Fair value adj. for equity security investments	0.04			(0.02	)
Adjusted Diluted EPS	$5.10			$5.19
Net earnings attributable to RBH				(0.06	)	(a)
Adjusted Diluted EPS	$5.10			$5.13		(b)
Currency	0.32
Adjusted Diluted EPS, excluding currency	$5.42			$5.13		(b)	~6%
(a) Net reported diluted EPS attributable to RBH from January 1, 2019 through March 21, 2019.
(b) Pro forma.

2020 Full-Year Forecast Assumptions

The assumptions underlying this forecast remain unchanged versus those communicated by PMI in its earnings release of October 20, 2020, with the exception of the following additions:

• Full-year HTU shipment volume of 75 to 76 billion units, broadly in-line with anticipated HTU in-market sales volume; and
• Strong sequential HTU market share gains in key IQOS geographies in the fourth quarter.

This forecast excludes the impact of any future acquisitions, unanticipated or unquantifiable asset impairment and exit cost charges, future changes in currency exchange rates, further developments related to the U.S. Tax Cuts and Jobs Act, further developments pertaining to the judgment in the two Québec Class Action lawsuits and the Companies’ Creditors Arrangement Act (CCAA) protection granted to RBH, any unusual events, and any COVID-19-related developments different from the assumptions set forth in the company’s forecast.

Factors described in the Forward-Looking and Cautionary Statements section of this release represent continuing risks to these projections.

Forward-Looking and Cautionary Statements

This press release, the presentation and related discussion contain projections of future results and other forward-looking statements. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. In the event that risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those contained in such forward-looking statements. Pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, PMI is identifying important factors that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in any forward-looking statements made by PMI.

PMI’s business risks include: excise tax increases and discriminatory tax structures; increasing marketing and regulatory restrictions that could reduce our competitiveness, eliminate our ability to communicate with adult consumers, or ban certain of our products; health concerns relating to the use of tobacco and other nicotine-containing products and exposure to environmental tobacco smoke; litigation related to tobacco use and intellectual property; intense competition; the effects of global and individual country economic, regulatory and political developments, natural disasters and conflicts; changes in adult smoker behavior; lost revenues as a result of counterfeiting, contraband and cross-border purchases; governmental investigations; unfavorable currency exchange rates and currency devaluations, and limitations on the ability to repatriate funds; adverse changes in applicable corporate tax laws; adverse changes in the cost and quality of tobacco and other agricultural products and raw materials; and the integrity of its information systems and effectiveness of its data privacy policies. PMI’s future profitability may also be adversely affected should it be unsuccessful in its attempts to produce and commercialize reduced-risk products or if regulation or taxation do not differentiate between such products and cigarettes; if it is unable to successfully introduce new products, promote brand equity, enter new markets or improve its margins through increased prices and productivity gains; if it is unable to expand its brand portfolio internally or through acquisitions and the development of strategic business relationships; or if it is unable to attract and retain the best global talent. Future results are also subject to the lower predictability of our reduced-risk product category’s performance.

The COVID-19 pandemic has created significant societal and economic disruption, and resulted in closures of stores, factories and offices, and restrictions on manufacturing, distribution and travel, all of which will adversely impact our business, results of operations, cash flows and financial position during the continuation of the pandemic. Our business continuity plans and other safeguards in place may not be effective to mitigate the impact of the pandemic. Currently, significant risks include our diminished ability to convert adult smokers to our RRPs, significant volume declines in our duty-free business and certain other key markets, disruptions or delays in our manufacturing and supply chain, increased currency volatility, and delays in certain cost saving, transformation and restructuring initiatives. Our business could also be adversely impacted if key personnel or a significant number of employees or business partners become unavailable due to the COVID-19 outbreak. The significant adverse impact of COVID-19 on the economic or political conditions in markets in which we operate could result in changes to the preferences of our adult consumers and lower demand for our products, particularly for our mid-price or premium-price brands. Continuation of the pandemic could disrupt our access to the credit markets or increase our borrowing costs. Governments may temporarily be unable to focus on the development of science-based regulatory frameworks for the development and commercialization of RRPs or on the enforcement or implementation of regulations that are significant to our business. In addition, messaging about the potential negative impacts of the use of our products on COVID-19 risks may lead to increasingly restrictive regulatory measures on the sale and use of our products, negatively impact demand for our products, the willingness of adult consumers to switch to our RRPs and our efforts to advocate for the development of science-based regulatory frameworks for the development and commercialization of RRPs.

The impact of these risks also depends on factors beyond our knowledge or control, including the duration and severity of the outbreak, its recurrence in our key markets, actions taken to contain its spread and to mitigate its public health effects, and the ultimate economic consequences thereof.

PMI is further subject to other risks detailed from time to time in its publicly filed documents, including the Form 10-Q for the quarter ended September 30, 2020. PMI cautions that the foregoing list of important factors is not a complete discussion of all potential risks and uncertainties. PMI does not undertake to update any forward-looking statement that it may make from time to time, except in the normal course of its public disclosure obligations.

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables to Altria Group, Inc. for sale under license in the U.S., where the U.S. Food and Drug Administration (FDA) has authorized their marketing as a modified risk tobacco product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of September 30, 2020, PMI estimates that approximately 11.7 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, available for sale in 61 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005544/en/

Investor Relations:

New York: +1 (917) 663 2233

Lausanne: +41 (0)58 242 4666

[email protected]

Media:

Lausanne: +41 (0)58 242 4500

[email protected]

KEYWORDS: United States North America Canada New York

INDUSTRY KEYWORDS: Tobacco Retail

MEDIA:

Logo

Bravo Multinational, Inc. Appoints Four New Members to “Business Advisory” Board

VIRGINIA BEACH, Va.–(BUSINESS WIRE)–
Bravo Multinational Incorporated (“Bravo Multinational” or the “Company”) (OTC: BRVO) announced the appointment of Mr. Mark Greenberg, Mr. Neil Davis, Mr. Stephen Scheffer and Mr. Edward Pergjini to the newly formed “Business Advisory” board, effective November 30, 2020. All four individuals have accepted their “Business Advisory” board seat positions.

Bravo Multinational created the “Business Advisory” board to assist the Company’s management and Board of Directors with the evaluation of business opportunities within the media, entertainment and sports industries as well as the electric metals and green alternative energy sectors. Each of the seated members has extensive experiences in these industries.

The Company filed a Form 8-K on December 1, 2020 with the United States Securities and Exchange Commission regarding the newly form “Business Advisory” board and its members.

Bios for the “Business Advisory” board members are below:

Mark Greenberg is the CEO of SEVN Sports Inc. He served as the Founder and Chief Executive Officer of EPIX from 2009 to 2017. As an early visionary in the video streaming industry, Mr. Greenberg led EPIX to become the first cross platform network and his work has influenced future streaming services including Netflix, Amazon and Hulu. Mr. Greenberg previously served as Executive Vice President for Showtime Networks, Inc., and Director of Direct Marketing at HBO (Home Box Office). Mr. Greenberg received his undergraduate degree from Providence College and his MBA from Columbia University.

Neil Davis is the Chief Business Development Officer of SEVN Sports Inc. Mr. Davis is a seasoned digital executive for various companies including, AOL, Blockbuster, Dish Network and Qello Media, where he served as Chief Business Officer. He was previously CEO at Monetize, where he consulted for the media and entertainment industries. Prior to that, he was Head of Corporate and Digital Development at Blockbuster-Dish Digital. Mr. Davis received his undergraduate degree from Arizona State University.

Stephen Scheffer has served almost 30 years at HBO (Home Box Office) as President of Film Programming, Video and Enterprises. Mr. Scheffer was responsible for overseeing all motion picture programming for HBO. As President of HBO Pictures, he was responsible for the financing and production of HBO’s Silver Screen Partners and Cinema Plus theatrical movie ventures. Prior to HBO, Mr. Scheffer held executive positions at Time Life Films, Allied Artists, Polydor Records, MGM and Columbia Pictures. Mr. Scheffer received his undergraduate degree from the United States Naval Academy in Annapolis, Maryland and his MBA from Harvard Business School.

Edward Pergjini is the President of Element Sports Group Inc, a wholly-owned subsidiary of Element Global, Inc. (OTC: ELGL) Mr. Pergjini has over 30-years of experience working with multinational companies across disciplines including, commercial strategy, team management, the construction and development of international brands, and the management of broad real estate heritages. He also has a strong understanding of cross-cultural marketing, along with deep expertise in the economic and financial workings of professional European soccer clubs. Mr. Pergjini resides in France and received his MBA from Fairleigh Dickinson University.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters disclosed at www.otcmarkets.com. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements

View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005502/en/

Sloane & Company

Erica Bartsch

Phone: 212-446-1875

Email: [email protected]

KEYWORDS: United States North America Virginia

INDUSTRY KEYWORDS: Professional Services Entertainment Other Professional Services Other Entertainment General Entertainment Consulting Casino/Gaming

MEDIA:

Posted on December 2, 2020 8:35 am

DXC Technology and Microsoft Collaborate to Power a More Personalized, Intelligent, Secure and Modern Workplace Experience for Global Enterprises

DXC Technology and Microsoft Collaborate to Power a More Personalized, Intelligent, Secure and Modern Workplace Experience for Global Enterprises

TYSONS, Va.–(BUSINESS WIRE)–DXC Technology (NYSE: DXC) today announced an expanded strategic collaboration with Microsoft to deliver a more personalized, intelligent, secure and modern workplace experience to help companies to address rapidly evolving business challenges and customer and employee needs.

DXC and Microsoft are joining forces to deliver a solution and suite of services that will help companies to empower their employees with a modern workplace experience and to ensure customers’ employees can seamlessly and securely work anytime, anywhere and on any device.

Called DXC MyWorkStyle™, DXC brings the largest install base of workplace customers and the blueprint for the modern workplace experience. As part of the collaboration, Microsoft and DXC will work together to co-develop and deliver the solution, leveraging artificial intelligence and machine learning from millions of data points to create a modern workplace experience.

DXC and Microsoft will bring together leading technology, engineering talent and architects to enhance the DXC MyWorkStyle platform. The platform will leverage Microsoft’s suite of services including Microsoft 365 and Teams, and Dynamics 365 and Power Platform.

Together, our goal is to bring customers a next level employee experience and to unlock further value in the workplace. DXC’s partnership with Microsoft is a game changer, with both companies committed to changing the future of work forever. DXC will be customer number one, creating the modern workplace experience for themselves. DXC is already working to implement and adopt the DXC MyWorkStyle platform to create a better experience for its own people, globally.

As the world’s largest provider of workplace services, DXC supports more than 1,000 workplace customers in 67 countries. The company manages over 7.2 million devices and 1.3 million desktops virtually, nearly two-times its closest competitor. DXC also manages over 8.2 million Microsoft Office 365 and Teams seats and responds to more than 40 million requests for support each year in 56 languages.

“We are excited about our modern workplace business and our partnership with Microsoft,” said Mike Salvino, DXC president and chief executive officer. “The world of work has changed forever and working virtually is now a ‘must’ for all businesses. This is a great opportunity for customers of both Microsoft and DXC to help their employees to work without disruption and provide a truly virtual, modern workplace experience that allows them to be more productive, more engaged and more connected to their teammates.

“As we explored strategic alternatives over recent months, we realized that keeping this business provides the opportunity to define the future of work and create much more value for our customers and our people.”

“Enterprise customers are accelerating deployment of cloud-based services to enhance employee experiences, facilitate better decision making based on data-driven insights and engage customers in new ways,” said Judson Althoff, executive vice president of Microsoft’s worldwide commercial business. “We are excited by our enhanced collaboration with DXC that will help enterprise customers evolve their cloud strategies and realize their business transformation.”

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy the Enterprise Technology Stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005481/en/

Richard Adamonis, Corporate Media Relations, +1.862.228.3481, [email protected]

Shailesh Murali, Investor Relations, +1.703.245.9700, [email protected]

KEYWORDS: Virginia Ireland Denmark Norway Finland Sweden United States South America United Kingdom Central America North America Middle East Asia Pacific Europe Canada

INDUSTRY KEYWORDS: Data Management Consumer Electronics Technology VoIP Mobile/Wireless Human Resources Finance Semiconductor Security Satellite Photography Nanotechnology Professional Services Other Technology Audio/Video Telecommunications Software Networks Internet Hardware Electronic Design Automation

MEDIA:

Logo

OriginClear Maintains Momentum, Outpacing First Nine Months of 2019

Revenue for nine months ended September 30, 2020 increased over nine months ended September 30, 2019

CLEARWATER, Fla.–(BUSINESS WIRE)–OriginClear Inc. (OTCQB: OCLN), The Water Company for the New Economy™, announces that revenues and gross profits for the first nine months of 2020 outpaced the same period in 2019.

The company reported the following highlights from its recent quarterly report:

• Revenue for the nine months ended September 30, 2020 increased by 14% to $3,064,758 compared to $2,696,433 for the same period last year.
• Gross profit for the same period increased by 20% to $348,176 compared to $290,294 last year.
• Loss from operations for the same nine months ended September 30, 2020 decreased by 5% to $2,682,435 compared to $2,836,416 for the same period last year.

“Thanks to the hard work of our Texas-based team, we are continuing to outpace 2019,” said Riggs Eckelberry, OriginClear CEO. “Even more importantly, we saw a boost in booked orders late in the third quarter, including approximately $450,000 in jobs in progress which have not yet been recognized.”

“I’m pleased with the pace of new business on Progressive Water Treatment and Modular Water Systems,” said Tom Marchesello, OriginClear Chief Operating Officer. “Our team efforts are paying off.”

Revenue for the three months ended 9/30/20 decreased by 2% to $917,320 compared to $939,468 for the same period last year. The three months ended September 30, 2020 showed a Gross Loss, $(17,388) vs $80,640 and Loss from operations widened to $1,183,722 from $964,655.

Follow us on Twitter

Like us on Facebook

Signup for our Newsletter

About OriginClear, Inc.

Water is our planet’s most valuable resource, and the mission of OriginClear is to provide breakthrough water treatment and conveyance products that effectively improve the quality of our planet’s waters by returning them to their original and clear condition and deliver the highest quality water to end-users. But 80% of all sewage in the world is never treated, and up to 35% of all clean water is lost in transit. This calls for self-help solutions at the point of use, a movement known as decentralized water treatment. Our mission is to enable this decentralized water revolution by providing rapid deployment, point-of-use water treatment and conveyance products and technologies that enable water independence, and help make clean water available for all. For more information, visit the company’s website at www.OriginClear.com.

Forward-Looking Statements

Matters discussed in this presentation contain forward-looking statements. When used in this update, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with our history of losses and our need to raise additional financing, the acceptance of our products and technology in the marketplace, our ability to demonstrate the commercial viability of our products and technology and our need to increase the size of our organization. Further information on the Company’s risk factors is contained in the Company’s quarterly and annual reports as filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason except as may be required under applicable law. There cannot be any assurance that our revenue will increase.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005344/en/

Investor Relations OriginClear:

Devin Angus

Toll-free: 877-999-OOIL (6645) Ext. 3

International: +1-323-939-6645 Ext. 3

Fax: 323-315-2301

[email protected]

www.OriginClear.com

Press Contact:

TransMedia Group

Dilara Tuncer, Director of Public Relations

941-549-3571

[email protected]

www.transmediagroup.com

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Manufacturing Other Natural Resources Mining/Minerals Other Energy Agriculture Utilities Natural Resources Oil/Gas Environment Energy Engineering

MEDIA:

Logo

Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted

LOS ANGELES–(BUSINESS WIRE)–
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has prevailed in final appeal proceedings brought against its licensed European patent EP Patent 1848414, which covers the use of irreversible EGFR inhibitors in treating gefitinib and/or erlotinib resistant cancer and cancer with a T790M EGFR mutation. The European Board of Appeals announced its decision at a hearing on December 1st, rejecting the opposition of EP Patent 1848414 initiated by a Boehringer Ingelheim entity.

The EP Patent 1848414 originally granted in April 2011 covers the use of irreversible EGFR inhibitors in treating gefitinib and/or erlotinib resistant cancer and cancer with a T790M EGFR mutation. On November 28, 2011, an opposition was filed seeking invalidation of the patent. The Opposition Division of the European Patent Office issued a decision on February 4, 2014 revoking some claims but upheld a subset of the granted claims relating to a pharmaceutical composition for use in treating cancer in a subject having a T790M EGFR mutation without any modification. Both parties appealed that decision in 2017. At a final hearing, the Board of Appeals announced its decision, concluding that the opposition was inadmissible and reversing the European Opposition Division decision issued in 2014, thereby upholding the EP Patent 1848414 as originally granted.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005287/en/

Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500

[email protected]

[email protected]

David Schull or Maggie Beller, Russo Partners, +1 212 845 4200

[email protected]

[email protected]

KEYWORDS: California Europe United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo

Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (“LSD”) to Treat Parkinson’s Disease

Collaboration with the University of Maastricht of the Netherlands

TEANECK, N.J.–(BUSINESS WIRE)–
Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an investigator-sponsored study agreement with Maastricht University of the Netherlands. The research project is a clinical study to examine the effects of repeated low doses of psilocybin and LSD on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action.

Dr. Kim Kuypers, Associate Professor, Department of Neuropsychology and Psychopharmacology at Maastricht University, will serve as Investigator Sponsor for the Phase 2B study. Dr. Kuypers’ main topics of interest are MDMA and psychedelics and their effects on (social) cognition, creativity, hormones, and underlying brain mechanisms.

“The signing of this clinical study agreement represents a significant milestone for the Company as we continue our work to bring novel therapeutics to patients in need,” stated Eric Weisblum, Chairman and CEO of Silo Pharma. “Dr. Kuypers is one of the world’s foremost clinical investigators in the field of psychedelics and has previously evaluated the concept of micro-dosing in her research.”

The Phase 2B study is a human study to be conducted on a sufficient number of patients, the primary purpose of which is to evaluate the safety and efficacy of psilocybin and LSD on patients suffering from Parkinson’s disease. The primary objective of this trial is to investigate the effects of repeated low doses of psilocybin and LSD on well-being and affect (self-rated), emotional and cognitive attention (computer tasks), and biological markers of neuroplasticity. Secondary objectives are to investigate the effects of repeated low doses of psilocybin and LSD on cognitive performance measures of memory and executive functioning, known to be impaired in Parkinson’s disease (computer tasks) and emotion regulation Parkinson’s symptoms, and biological markers of well-being (immune system, cortisol).

“Parkinson’s disease is a progressive nervous system disorder that affects 7-10 million people globally and currently has no cure,” added Mr. Weisblum. “Our goal, in collaborating with Maastricht University and Dr. Kuypers, is to bring hope to those suffering with this terrible disease. We expect to share additional information regarding protocol, ethics submission and initiation of the study as the information becomes available.”

About Silo Pharma

Silo Pharma, Inc. is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry. For more information, visit www.silopharma.com.

Safe Harbor and Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005179/en/

Investor Relations Contact:

Hayden IR

Brett Maas

646-536-7331

Email: [email protected]

KEYWORDS: Netherlands Europe

INDUSTRY KEYWORDS: Mental Health Health Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA: